Please provide your email address to receive an email when new articles are posted on . In September 2007, the FDA approved dexrazoxane hydrochloride injection for the treatment of extravasation ...

Please provide your email address to receive an email when new articles are posted on . Extravasation reactions are some of the most devastating adverse effects of anthracycline antineoplastic agents.

October 3, 2006 (Istanbul) — Prompt use of dexrazoxane reduces the devastating damage that can result from extravasation due to anthracycline drugs and can prevent the need for surgery, according to ...

Biocodex USA announced today its acquisition of the oncology supportive care product, Totect from Apricus Biosciences. Totect (dexrazoxane HCl) is the only FDA-approved treatment for anthracycline ...

Company will use funds to push on with late-stage development and commercialization of cancer drug Belinostat. SpePharm is paying €6 million, or about $8.17 million, for worldwide rights except in ...

Anthracycline chemotherapy drugs damage the DNA in cancer cells, so they cannot reproduce. They can treat several types of cancer. However, they can also cause a range of side effects. Anthracycline ...

Burton-on-Trent, UK – 31 March 2014 – Clinigen Group plc ('Clinigen' or the 'Group') (LSE: CLIN) (AIM: CLIN) the specialty global pharmaceutical company today announces the acquisition of SAVENE® ...

Clinigen acquires US-approved Totect® (dexrazoxane) from Biocodex to become the only global source for the treatment of anthracycline extravasation Clinigen Group plc (AIM: CLIN, 'Clinigen' or the ...

Clinigen Group plc ('Clinigen' or the 'Group') (LSE: CLIN) (AIM: CLIN) the specialty global pharmaceutical company today announces the acquisition of SAVENE ® (dexrazoxane) from SpePharm AG, a ...